Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular ’Piggyback Ride’ carries Alzheimer’s protein into brain

24.06.2003


Scientists studying the brains of mice have discovered how the toxic protein that destroys the brain cells of Alzheimer’s patients enters the brain. When the researchers gave mice a drug that blocked the process, flow of the protein into the brain was virtually halted and existing accumulations of it in the brain plummeted by more than 70 percent. The results of the research will be published in the July 1 issue of Nature Medicine.



The new findings center on amyloid beta, a tiny protein molecule that accumulates over time to form tell-tale plaques in the brain tissue of Alzheimer’s patients. While various cells within the brain itself produce amyloid beta, that amount may be just the tip of the iceberg. Mounting evidence suggests that the bulk of amyloid beta is produced in cells throughout the body and gets circulated in the blood. The new study reveals for the first time how the protein gets from the blood into the brain, thwarting the brain’s elaborate filtration mechanism that normally keeps away toxins. In mice that had been genetically engineered to develop Alzheimer’s, the process ran wild, pouring amyloid beta into the brain at eight times the rate of healthy mice.

"For more than a decade we’ve known that this protein wreaks havoc in the brains of Alzheimer’s patients, but we haven’t known how it gets there or how to prevent it from getting there. This study answers both of those basic questions, and opens an entirely new avenue for the treatment of Alzheimer’s disease," said lead author Berislav Zlokovic, M.D., Ph.D., of the University of Rochester Medical Center.


Since 1992, Zlokovic’s research has focused on how amyloid beta protein in the blood is able to pass through the blood-brain barrier, a thin layer of cells that lines the inner walls of the brain’s blood vessels. The blood-brain barrier blocks the passage of toxins while allowing the flow of oxygen, sugar, and other nutrients to brain cells. In the current study, Zlokovic and his colleagues found that amyloid beta protein molecules cannot flow through the blood-brain barrier unaided. Rather, they get through by riding piggyback on a much larger molecule, called RAGE, which is nontoxic and moves unfettered across the blood-brain barrier. Normally, RAGE is produced in small amounts by the cells that form the blood-brain barrier. But in mice that were genetically engineered to develop Alzheimer’s disease, Zlokovic found that RAGE was produced in huge amounts – eight times normal – and ferried an avalanche of amyloid beta into the brain.

Zlokovic became interested in RAGE several years ago while studying amyloid beta proteins that had been culled from the brains of Alzheimer’s patients who, years before their deaths, had agreed to donate their brains to the University’s Alzheimer’s research program. In the donated brain tissue, Zlokovic spotted something he hadn’t seen before: Some of the amyloid beta proteins were attached to much larger molecules. The larger molecules turned out to be RAGE (short for receptor for advanced glycation end products), which had been observed in brain tissue by other researchers, but whose function was a mystery. Zlokovic’s new study was conceived as a series of experiments designed to solve it.

In the first experiment, he injected mice with an agent, called anti-RAGE, that binds to RAGE molecules and disables them, making them unable to bind with amyloid beta proteins. Then he injected amyloid beta proteins into the mice and observed that, with the RAGE molecules disabled, transport of the amyloid beta proteins across the blood-brain barrier came to a sudden halt.

In another experiment, he administered a RAGE look-alike, called soluble RAGE. The soluble RAGE molecules attached themselves to amyloid beta proteins, but unlike RAGE, were unable to transport the proteins across the blood-brain barrier. With the amyloid beta proteins bound to the soluble RAGE molecules, however, the RAGE molecules naturally present in the mice were not able to bind to the proteins. In this experiment, like the first, the flow of amyloid beta across the blood-brain barrier also stopped abruptly.

With evidence that RAGE was involved in the transport of amyloid beta across the blood-brain barrier, the research team obtained mice in which the gene that produces the RAGE molecule was disabled or "knocked out" by genetic engineering. When the researchers injected amyloid beta protein into these mice, none of it crossed the blood-brain barrier, confirming RAGE’s function.

Another experiment was conducted in mice that were genetically engineered to develop Alzheimer’s disease. In half of the mice the team administered soluble RAGE once a day; the remaining mice were not given the agent. After three months, the researchers compared the amyloid beta levels in the brains of each group. In the group that had received soluble RAGE, both the amount of amyloid beta protein in their brains and the size of amyloid plaques were reduced by 70 percent compared to the mice that did not receive the agent.

The researchers also found that as RAGE transported increased levels of amyloid beta into the brain, blood flow within the brain was reduced by half. When soluble RAGE was administered to block the process, blood flow to the brain returned to normal. The new finding – that blood flow to the brain is sharply reduced in Alzheimer’s mice – suggests that decreased cerebral blood flow may partially account for the confusion and dementia that plague Alzheimer’s patients.

"The experiments in this study revealed a great deal of new information about Alzheimer’s disease," said Zlokovic. "First, it is now very clear that the body regulates the movement of amyloid beta proteins across the blood-brain barrier. Second, we’ve shown that that we can use a drug to stop the flow of amyloid beta from the blood to the brain. Finally, we learned that when we block the flow of amyloid beta over time, the brain substantially rids itself of amyloid beta and the amyloid plaques shrink dramatically.

"For patients with Alzheimer’s disease, these findings suggest that we can develop a new class of drugs that work by blocking the flow of the toxic Alzheimer’s protein into the brain," said Zlokovic.

The researchers are looking ahead to clinical trials of new drug candidates. They are planning studies to determine whether soluble RAGE is likely to be safe when administered to people, and are working to identify other molecules that work in the same way as soluble RAGE.


###
Collaborators in the study, which was funded by a grant from the National Institutes of Health, included Mark Kindy, Ph.D., from the University of South Carolina and David Stern, Ph.D. and Shi Du Yan, Ph.D. from Columbia University.

Christopher DiFrancesco | EurekAlert!
Further information:
http://www.urmc.rochester.edu/

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>